A randomized phase II study investigating cilengitide added to standard chemoradiotherapy in patients with newly diagnosed glioblastoma with unmethylated O-6-methylguanine-DNA methyltransferase (MGMT) gene promoter: Initial report of the CORE study
EUROPEAN JOURNAL OF CANCER（2013）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined